The Relationship Between Adherence to Oral Antidiabetic
Medication and Fasting Blood Glucose Control in Type 2 Diabetes Mellitus
Patients at Palmerah District Health Center in 2024
Pramudita Permatasari1*,
Hari Sutanto2
1,2Universitas Tarumanagara,
Indonesia
Email: pramudita.405210185@stu.untar.ac.id1,
dr.hari.sutanto@gmail.com2
|
KEYWORDS |
ABSTRACT |
|
medication
adherence, type 2 diabetes mellitus, fasting blood glucose. |
Type
2 diabetes mellitus is a metabolic disease characterized by hyperglycemia due
to impaired insulin secretion or function. Data from the Indonesian Ministry
of Health in 2021 reported 19.47 million Indonesians living with diabetes.
This research evaluated the impact of adherence to oral antidiabetic
medication on fasting blood glucose control in type 2 diabetes patients at
Palmerah Subdistrict Health Center. A cross-sectional analytic design was
used with 52 respondents selected via consecutive sampling. Data were
obtained through medical records and the MARS-5 questionnaire. Of the
respondents, 55.8% (n=29) were female, and 44.2% (n=23) were male. Adherence
to medication regimens was evenly distributed, with 25 patients (50%)
adhering and 25 (50%) not adhering. Analysis showed significant differences
in fasting blood glucose control. In the adherent group, 92.6% (n=25)
achieved controlled blood glucose levels, while all non-adherent patients
(100%) had high fasting blood glucose levels. Fisher's Exact test results
(p=0.000) confirmed a significant relationship between adherence and blood
glucose control. These findings highlight that medication adherence is
crucial in managing type 2 diabetes. Practical implications include the need
for targeted strategies to enhance adherence, such as patient education,
reminders, and personalized support. Factors such as demographics,
comorbidities, memory decline, and BMI also influence adherence, requiring a
comprehensive approach. Consistent adherence improves glycemic control,
reduces complications, and is essential for effective diabetes management. |
|
DOI: 10.58860/ijsh.v4i1.276 |
|
Corresponding Author: Pramudita Permatasari*
Email: pramudita.405210185@stu.untar.ac.id
INTRODUCTION
Type 2
diabetes mellitus (DM) is a group of metabolic disorders characterized by
chronic hyperglycemia due to impaired insulin secretion, insulin action, or
both, which disrupt carbohydrate, fat, and protein metabolism
The
International Diabetes Federation (IDF) reported in 2021 that 537 million
adults (20–79 years old) worldwide are living with diabetes, with this number
projected to rise to 643 million by 2030 and 784 million by 2045
In Indonesia,
the prevalence of diabetes has reached critical levels. The Ministry of Health
of the Republic of Indonesia reported that in 2021, 19.47 million people were
living with diabetes, highlighting the pressing need for effective management
and prevention strategies. With type 2 DM being a significant contributor to
this burden, addressing the factors that impact disease management,
particularly adherence to therapy, is of national importance
Therapeutic
adherence, defined as a patient's ability to follow medical instructions, such
as maintaining a proper diet, engaging in physical activity, taking prescribed
medications, and attending regular checkups, plays a vital role in achieving
optimal glycemic control. However, non-adherence is a widespread issue,
affecting 40–50% of patients with chronic conditions like diabetes
Despite the
significant burden of type 2 DM in Indonesia, limited studies have specifically
explored the relationship between adherence to oral antidiabetic therapy and
blood glucose control at the community level. This research seeks to fill that
gap by examining this relationship in type 2 DM patients at the Palmerah
District Health Center in 2024
Based on the
background above, the objective of this research is to analyze the relationship
between adherence to oral antidiabetic therapy and blood glucose control in
type 2 diabetes mellitus (DM) patients at the Palmerah District Health Center
in 2024. This research aims to identify adherence patterns and evaluate their
impact on glycemic control to provide a better understanding of the factors
influencing effective diabetes management. The benefits of this research are
expected to contribute to improving diabetes management strategies at the
community level. By identifying the correlation between therapeutic adherence
and blood glucose control, this research can serve as a basis for designing
targeted interventions to enhance patient compliance with prescribed therapies.
Additionally, the findings of this research can provide evidence-based
recommendations for healthcare providers and policymakers to optimize treatment
outcomes, reduce complications, and improve the quality of life for patients
with type 2 DM in Indonesia.
METHOD
This research employs a cross-sectional
analytical research design targeting type 2 DM patients at the Palmerah
District Health Center. The aim is to evaluate the relationship between
adherence to oral antidiabetic medication and fasting blood glucose control in
type 2 DM patients, conducted in July 2024. The research sample consists of 52
patients selected based on predetermined inclusion and exclusion criteria.
Adherence to oral antidiabetic medication serves as the independent variable, while fasting blood glucose levels are the
dependent variable. The MARS-5 questionnaire, a validated tool for assessing
medication adherence, and medical records were utilized as research instruments
to ensure reliability and accuracy. To reduce potential bias, external factors
influencing adherence and glucose levels, such as comorbid conditions and
lifestyle factors, were controlled during data collection. Data were analyzed
using the IBM SPSS software with univariate and bivariate analysis, employing
Fisher's Exact test for statistical evaluation.
RESULT AND DISCUSSION
The majority
of respondents were 29 women (55.8%), while 23 men (44.2%). Most patients had
75.0% comorbidities. The majority of patients underwent monotherapy, 76.9%,
while 23.1% used a combination of two drugs.
Table 1. The majority of
patients underwent monotherapy
|
|
Sum |
|
|||
|
Characteristic |
N |
% |
|
||
|
Man |
23 |
44.2% |
|
||
|
Woman |
29 |
55.8% |
|
||
|
Exist |
39 |
75.0% |
|
||
|
Not |
13 |
25.0% |
|
||
|
Combination
of 2 drugs |
12 |
23.1% |
|
||
|
Monotherapy |
40 |
76.9% |
|
||
|
<30
years |
1 |
1.9 |
|
||
|
30-40
years old |
3 |
5.8 |
|||
|
41-50
years old |
14 |
26.9 |
|||
|
51-60
years old |
32 |
61.5 |
|||
|
>60
years |
2 |
3.8 |
|||
|
GDP
Normal |
25 |
48.1 % |
|||
|
High
GDP |
27 |
51.9 % |
|||
|
Obey
Taking Medicine |
26 |
50.0 % |
|||
|
Not
Complying with Taking Medication |
26 |
50.0 % |
|||
Most
patients were in the age range of 51–60 years (61.5%), followed by 41–50 years
old (26.9%), and the rest were in a smaller percentage. A total of 26 patients
(50.0%) were included in the complaint category, and another 26 patients
(50.0%) were non-compliant. Then, 25 people (48.1%) had normal blood glucose
levels, while 27 people (51.9%) had high blood glucose levels.
Table
2. 27 people (51.9%) had high blood glucose levels
|
|
Medication
Compliance |
|
|||||||||||
|
Characteristic
Category |
Obedient |
Non-Compliance |
Total |
|
|||||||||
|
N |
% |
N |
% |
N |
% |
|
|||||||
|
Education |
Junior
high school equivalent |
4 |
80% |
1 |
20% |
5 |
100% |
||||||
|
High
school equivalent |
8 |
40% |
12 |
60% |
20 |
100% |
|||||||
|
Diploma |
4 |
50% |
4 |
50% |
8 |
100% |
|||||||
|
Sarjana |
11 |
57.9% |
8 |
42.1% |
19 |
100% |
|||||||
|
Categories
IMT |
Normal |
10 |
50% |
10 |
50% |
20 |
100% |
||||||
|
Overweight |
8 |
57.1% |
6 |
42.9% |
14 |
100% |
|||||||
|
Obesity |
9 |
50% |
9 |
50% |
18 |
100% |
|||||||
|
Therapy |
Monotherapy |
21 |
52.5% |
19 |
47.5% |
40 |
100% |
||||||
|
Combination
of 2 drugs |
6 |
50% |
6 |
50% |
12 |
100% |
|||||||
|
Comorbid |
Exist |
19 |
48.7% |
20 |
51.3% |
39 |
100% |
||||||
|
None |
8 |
61.5% |
5 |
38.5% |
13 |
100% |
|||||||
Junior
high school education at the same level showed the highest level of compliance,
which was 80%, with the other 20% not complying. In contrast, the lowest level
of compliance was found in high school education equivalent, which was 40%
compliant, while 60% were non-compliant. Diploma and undergraduate education have
compliance in the range of 50– 57.9%. Normal weight and obese patients showed
an adherence rate of 50%, while another 50% did not comply. The compliance
category level is 57.1%, slightly higher than other categories. Based on the
type of therapy, 21 people (52.5%) from the monotherapy group adhered to it,
while 19 people (47.5%) did not comply. In the group that used the combination
of two drugs, the compliance rate was 50%, with the same amount. Respondents
without comorbidities showed a higher level of compliance, namely 8 people
(61.5%) compared to 5 people (38.5%) who did not comply. In contrast, in the
group with comorbidities, only 19 people (48.7%) were compliant, while 20 people (51.3%) were not compliant.
Table
3. 20 people (51.3%) were not compliant
|
|
GDP
Rate |
||||||
|
Characteristic |
Category |
Usually |
Tall |
Total |
|||
|
% |
N |
% |
N |
% |
N |
||
|
Categories IMT |
Usual |
9 |
45% |
11 |
55% |
20 |
100% |
|
Overweight |
7 |
50% |
7 |
50% |
14 |
100% |
|
|
Obesity |
9 |
50% |
9 |
50% |
28 |
100% |
|
|
Comorbid |
Exist |
18 |
46.2% |
21 |
53.8% |
39 |
100% |
|
None |
7 |
53.8% |
6 |
46.2% |
13 |
100% |
|
A
total of 9 people (45%) have normal GDP levels, while
11 people (55%) have high GDP levels. In the overweight group, the proportion
of normal and high GDP levels was balanced, with as many as 7 people (50%)
each. Meanwhile, in the obesity category, the distribution is also the same,
namely 9 people (50%) with normal GDP levels and 9 people (50%) with high GDP
levels. In terms of the characteristics of comorbidities, respondents who had
comorbidities showed a higher skewed distribution of GDP levels. A total of 18
people (46.2%) have normal GDP levels, while 21 people
(53.8%) have high GDP levels. In contrast, respondents without comorbidities
showed a different proportion, where more respondents had normal GDP levels (7
people or 53.8%) than high GDP levels (6 people or 46.2%). Of the 27 patients
who adhered to oral antidiabetic drugs, as many as 25 people (92.6%) had normal
fasting blood glucose levels, while only 2 people (7.4%) had high blood glucose
levels. In contrast, of the 25 non-compliant patients, all
(100%) had high blood glucose levels.
Table
4. all (100%) had high blood glucose levels
|
Control of Fasting Blood Glucose Levels |
||||||||
|
|
|
Usual |
|
Tall |
|
Total |
|
Fisher’s Exact (-sided) |
|
|
|
N |
% |
N |
% |
N |
% |
|
|
Medication Compliance |
Obedient Non-compliant |
25 |
92.6% |
2 |
7.4% |
27 |
100% |
P-Value 0.000 |
|
|
|
0 |
0.0% |
25 |
25% |
25 |
100% |
|
|
Total |
|
25 |
48.1% |
27 |
51.9% |
52 |
100% |
|
Based
on the Fisher's Exact test table above, the analysis results show a
significance value (p-value) of 0.000. This indicates a significant
relationship between the level of adherence to taking oral antidiabetic drugs
and the control of fasting blood glucose levels in patients with type 2
diabetes mellitus. In addition, the Pearson Chi-Square results also showed a
significance value of 0.000, assuming the expected frequency was met because
there were no cells with a value of less than 5. Thus, both Fisher's Exact Test
and Chi-Square support the conclusion that there is a significant relationship
between the two variables tested.
PRR was
calculated by dividing the risk of high blood glucose levels in the
non-compliant group by the risk of high blood glucose levels in the compliant
group. Of the 27 patients who obeyed, as many as 25 patients (92.6%) had normal
fasting blood glucose levels. A total of 2 patients (7.4% or 0.074) were at
risk of high blood glucose levels. Of the 25 non-compliant patients, all (100%)
had high blood glucose levels. The risk of having high blood glucose levels in
this group is 100% or 1.0.
PRR = Non-compliant
group risk: Compliance group risk
PRR = ![]()
PRR = = 13.51![]()
Non-compliant
patients had a 13.51 times greater risk of having high blood glucose levels
compared to compliant patients. This shows a very strong relationship between
adherence to oral antidiabetic medication and control of fasting blood glucose
levels.
Based on
gender, the majority of respondents were women, as many as 29 people (55.8%),
while male respondents amounted to 23 people (44.2%). This finding is
comparable to the results of a research conducted, which shows that the number
of female respondents is more than men. There are factors that increase the
risk of diabetes mellitus, including obesity, high-stress levels, pregnancy
history, and the use of oral contraceptives. 8 However, several studies,
including those conducted, show that there is no relationship between gender
and the level of adherence to taking anti-diabetic drugs in type 2 DM patients.
Nevertheless, the results of previous studies still support this research,
which suggests that female patients tend to be more obedient than male
patients.10 reviews
Patients with
a junior high school education or equivalent tend to have the highest levels of
adherence to treatment, followed by individuals with a bachelor's education
The results of
the findings of patient comorbidities showed that most of the patients had
comorbidities, namely 39 people (75.0%), while those who did not have
comorbidities were 13 people (25.0%). Research shows that the more complex a
treatment regimen is, the more difficult it is for patients to remember and
follow all treatment instructions, potentially lowering adherence levels. These
findings are comparable to research conducted by Moh Rasyid Kuna et al.
Based on
therapy, the results showed that monotherapy, namely the use of one type of
drug, was the most dominant treatment approach, with a total of 40 people
(76.9%), while the remaining 12 people (23.1%) used a combination of two drugs.
Based on data, 52.5% of patients using monotherapy consistently consumed drugs
according to the recommendations, while in the combination therapy group, the
percentage of compliance only reached 50%. This suggests that the type of
therapy can affect patient adherence, where more complex combination therapies
may decrease patient consistency in following prescribed medications. According
to the research of Rasdianah et al.
According to WHO
guidelines, obesity is a condition characterized by a significant increase in
body fat mass due to an imbalance between energy intake and energy expenditure
Quoted by
Andriana et al.
The results
showed a significant relationship in the level of adherence to oral
antidiabetic treatment between groups with normal and abnormal fasting glucose
levels. All respondents with normal fasting blood glucose levels complied with
treatment, while only 7.14% of respondents with abnormal fasting blood glucose
levels complied. Based on the results of the interview research, information
was obtained that some respondents' non-compliance was caused by leisure
factors, such as busyness daily activities that can increase the risk of
forgetfulness in respondents, some respondents also admitted that they should
not consume oral antidiabetics because they felt that they did not experience
symptoms of the disease or felt bored with continuous treatment. This can be a
barrier for patients to maintain long-term compliance.
The results of
the research by Nanda et al.
The results of
this research are in line with research conducted by Deby A. Mpila et al.
Behind the
existence of obedient patients, there are patients who do not comply with
carrying out treatment steps according to the doctor's or clinical
recommendations. According to the World Health Organization (WHO),
non-compliance refers to a condition in which a patient does not or only
partially follows the treatment guidelines that have previously been agreed
upon with the doctor. According to the International Diabetes Federation (IDF),
the common understanding is that diabetes mellitus is a chronic disease that
requires long-term management, and the associated psychological burden can be a
barrier to patient adherence to treatment. According to Sari
Researchers
assume that adherence to the treatment regimen is a crucial factor in achieving
the main goal of type 2 DM therapy, which is to optimize fasting blood glucose
control. Thus, the risk of long-term complications such as cardiovascular
disease, nephropathy, and neuropathy can be minimized
CONCLUSION
A research of 52 respondents with type 2 diabetes mellitus at the
Palmerah District Health Center revealed that adherence to oral antidiabetic
treatment significantly contributes to the control of blood glucose levels. The
majority of respondents, predominantly women aged 51–60 years, demonstrated
that 92.6% of those adhering to their medication regimen achieved optimal blood
glucose control. The Fisher's Exact test analysis yielded a significant value
(p = 0.000), indicating a strong relationship between medication adherence and
fasting blood glucose control. Various factors, including individual
characteristics such as gender, education level, memory, comorbidities, and
body mass index (BMI), as well as treatment factors like the number of
medications, frequency, and regimen complexity, influence patient adherence.
These findings
underscore the critical role of adherence to oral antidiabetic treatment in
managing type 2 diabetes mellitus. To enhance adherence, education-based
interventions should focus on patient-centered approaches, such as providing
clear, accessible information about diabetes management, using visual aids to
simplify complex regimens, and incorporating reminders or digital tools to
improve memory and consistency. From a public health policy perspective,
efforts should include integrating diabetes management programs into primary
healthcare services, prioritizing health literacy campaigns, and advocating for
policies that promote the availability of affordable medications and support
streamlined treatment regimens. Strengthening collaboration between healthcare
providers and communities can further ensure sustainable adherence and improved
outcomes for diabetes management.
REFERENCES
Arnold, R., Issar, T., Krishnan, A. V, & Pussell, B. A.
(2016). Neurological complications in chronic kidney disease. JRSM
Cardiovascular Disease, 5, 2048004016677687.
Banat, H., Ambrus, R., & Csóka, I. (2023). Drug
combinations for inhalation: Current products and future development
addressing disease control and patient compliance. International Journal of
Pharmaceutics, 643, 123070.
https://doi.org/10.1016/j.ijpharm.2023.123070
De Lorenzo, A., Soldati, L., Sarlo, F., Calvani, M., Di
Lorenzo, N., & Di Renzo, L. (2016). New obesity classification criteria as
a tool for bariatric surgery indication. World
Journal of Gastroenterology, 22(2), 681.
Fonseca, D. C., Sala, P., de Azevedo
Muner Ferreira, B., Reis, J., Torrinhas, R. S., Bendavid, I., & Linetzky
Waitzberg, D. (2018). Body weight control and energy expenditure. Clinical
Nutrition Experimental, 20, 55–59.
https://doi.org/10.1016/j.yclnex.2018.04.001
Kardas, P. (2024). From non-adherence to adherence: Can
innovative solutions resolve a longstanding problem? European Journal of
Internal Medicine, 119, 6–12.
https://doi.org/10.1016/j.ejim.2023.10.012
Kenny, H. C., & Abel, E. D. (2019). Heart failure in
type 2 diabetes mellitus: impact of glucose-lowering agents, heart failure
therapies, and novel therapeutic strategies. Circulation Research, 124(1),
121–141.
Lawrence, R. E., Oquendo, M. A., & Stanley, B. (2016).
Religion and suicide risk: a systematic review. Archives of Suicide
Research, 20(1), 1–21.
Lima, J. E. B. F., Moreira, N. C. S., & Sakamoto-Hojo,
E. T. (2022). Mechanisms underlying the pathophysiology of type 2 diabetes:
From risk factors to oxidative stress, metabolic dysfunction, and
hyperglycemia. Mutation Research/Genetic Toxicology and Environmental
Mutagenesis, 874–875, 503437.
https://doi.org/10.1016/j.mrgentox.2021.503437
Lynch, P. (2022). Type 2 diabetes mellitus. Type 2
Diabetes Mellitus-Medical Independent.
Mishra, S., & Kishore, S. (2018). Effect of physical
activity during pregnancy on gestational diabetes mellitus. Indian Journal
of Endocrinology and Metabolism, 22(5), 661–671.
Paschal, A. M., Rush, S. E., & Sadler, T. (2014).
Factors associated with medication adherence in patients with epilepsy and
recommendations for improvement. Epilepsy & Behavior, 31,
346–350. https://doi.org/10.1016/j.yebeh.2013.10.002
Pratiwi, N., Samodra, G., Nawangsari, D., & Melani, R.
(2024). Formulation and iritaso test of ethanol extract gel of kersen bark
(muntingia calabura l.). Proceeding ICHBS, 1(1), 232–246.
Reach, G., Pechtner, V., Gentilella, R., Corcos, A., &
Ceriello, A. (2017). Clinical inertia and its impact on treatment
intensification in people with type 2 diabetes mellitus. Diabetes & Metabolism, 43(6), 501–511.
https://doi.org/10.1016/j.diabet.2017.06.003
Rimadania, D., Sari, E. A., & Sari,
C. W. M. (2021). Motivation and compliance to type 2 diabetes mellitus diet
in the work area of Puskesmas Padalarang. Journal of Community Empowerment
for Health, 4(2), 16–21.
Rusminingsih, E., & Purnomo, R. T. (2022). Relationship
of Patient Characteristics with Medication Adherence in Type 2 DM. Indonesian
Journal of Global Health Research, 4(3), 603–610.
Sitar-Tǎut, A.-V., Cozma, A., Fodor, A., Coste, S.-C.,
Orasan, O. H., Negrean, V., Pop, D., & Sitar-Tǎut, D.-A. (2021). New
insights on the relationship between leptin, ghrelin, and leptin/ghrelin ratio
enforced by body mass index in obesity and diabetes. Biomedicines, 9(11),
1657.
Sumarni, I., Baskara, I., & Fadli, J. A. (2024). The
Effect Of Service Quality And Destination Image On
Return Visit Intention Through Tourist Satisfaction. Jurnal Ilmiah
Manajemen Kesatuan, 12(6), 2309–2336.
van der Eng, P., & Sohn, K. (2018). Center for
Economic Institutions.
|
|
|